Trial Profile
A Prospective, Multinational, Multi-Center, Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy, Safety and Tolerability of siG12D-LODER in Combination With Standard of Care Chemotherapy in the Treatment of Patients With Locally Advanced Pancreatic Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Dec 2023
Price :
$35
*
At a glance
- Drugs Antisense K-ras RNA gene therapy (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Oxaliplatin; Paclitaxel
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Acronyms PROTACT
- Sponsors Silenseed
- 24 Oct 2023 Results (n=49) assessing a novel extended-release siRNA targeting KRASG12D/V (G12D/V) mutations (Loder) in combination with standard chemotherapy, presented at the 48th European Society for Medical Oncology Congress.
- 30 Jun 2021 Planned number of patients changed from 39 to 80.
- 30 Jun 2021 Planned End Date changed from 1 Jun 2020 to 1 Aug 2023.